Giannattasio S, Bobba A, Jurgelevicius V, Vacca R A, Lattanzio P, Merafina R S, Utkus A, Kucinskas V, Marra E
Consiglio Nazionale delle Ricerche, Istituto di Biomembrane e Bioenergetica, Bari, Italy.
Genet Test. 2006 Fall;10(3):169-73. doi: 10.1089/gte.2006.10.169.
Mutational analysis of the cystic fibrosis transmembrane regulator (CFTR) gene was performed in 98 unrelated CF chromosomes from 49 Lithuanian CF patients through a combined approach in which the p.F508del mutation was first screened by allele-specific PCR while CFTR mutations in nonp.F508del chromosomes have been screened for by denaturing gradient gel electrophoresis analysis. A CFTR mutation was characterized in 62.2% of CF chromosomes, two of which (2.0%) have been previously shown to carry a large gene deletion CFTRdele2,3(21 kb). The most frequent Lithuanian CF mutation is p.F508del (52.0%). Seven CFTR mutations, p.N1303K (2.0%), p.R75Q (1.0%), p.G314R (1.0%), p.R553X (4.2%), p.W1282X (1.0%), and g.3944delGT (1.0%), accounted for 10.1% of Lithuanian CF chromosomes. It was not possible to characterize 35.8% of the CF Lithuanian chromosomes. Analysis of intron 8 (TG)mTn and M470V polymorphic loci did not permit the characterization of the CFTR dysfunction underlying the CF phenotype in the patients for which no CFTR mutation was identified. Thus, screening of the eight CFTR mutations identified in this study and of the large deletion CFTRdele2,3(21 kb) allows the implementation of an early molecular or confirmatory CF diagnosis for 65% of Lithuanian CF chromosomes.
通过联合方法,对来自49例立陶宛囊性纤维化(CF)患者的98条不相关CF染色体进行了囊性纤维化跨膜传导调节因子(CFTR)基因的突变分析。首先通过等位基因特异性PCR筛查p.F508del突变,同时通过变性梯度凝胶电泳分析筛查非p.F508del染色体中的CFTR突变。在62.2%的CF染色体中鉴定出CFTR突变,其中两条(2.0%)先前已显示携带大基因缺失CFTRdele2,3(21 kb)。立陶宛最常见的CF突变是p.F508del(52.0%)。七种CFTR突变,p.N1303K(2.0%)、p.R75Q(1.0%)、p.G314R(1.0%)、p.R553X(4.2%)、p.W1282X(1.0%)和g.3944delGT(1.0%),占立陶宛CF染色体的10.1%。35.8%的立陶宛CF染色体无法鉴定其特征。对内含子8(TG)mTn和M470V多态性位点的分析,无法鉴定出未发现CFTR突变的患者中CF表型背后的CFTR功能障碍。因此,对本研究中鉴定出的八种CFTR突变以及大缺失CFTRdele2,3(21 kb)进行筛查,可为65%的立陶宛CF染色体实现早期分子诊断或CF确诊诊断。